Form 8-K - Current report:
SEC Accession No. 0000899923-24-000060
Filing Date
2024-11-26
Accepted
2024-11-26 16:42:07
Documents
14
Period of Report
2024-11-26
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mygn-20241126.htm   iXBRL 8-K 33217
  Complete submission text file 0000899923-24-000060.txt   183773

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mygn-20241126.xsd EX-101.SCH 2021
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mygn-20241126_def.xml EX-101.DEF 14426
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mygn-20241126_lab.xml EX-101.LAB 25279
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mygn-20241126_pre.xml EX-101.PRE 15012
16 EXTRACTED XBRL INSTANCE DOCUMENT mygn-20241126_htm.xml XML 2707
Mailing Address 322 NORTH 2200 WEST SALT LAKE CITY UT 84116
Business Address 322 NORTH 2200 WEST SALT LAKE CITY UT 84116 801-584-3600
MYRIAD GENETICS INC (Filer) CIK: 0000899923 (see all company filings)

EIN.: 870494517 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-26642 | Film No.: 241504677
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)